Real-world outcomes with immuno-oncology therapies in advanced melanoma: Final results of the OPTIMIzE registry study
Kirkwood JM, Kottschade LA, McWilliams RR, et al. Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study [published online ahead of print, 2023 Nov 8]. Immunotherapy. 2023;10.2217/imt-2022-0292. doi:10.2217/imt-2022-0292
Aim: The OPTIMIzE registry study evaluated real-world outcomes in patients with advanced melanoma receiving immuno-oncology therapies.
Materials and methods: Data were collected for patients treated with anti-programmed death 1 (PD-1) monotherapy (nivolumab or pembrolizumab; n = 147) or nivolumab plus ipilimumab (n = 81) from 2015-2017 and followed for ≥3 years.
Results: Nivolumab plus ipilimumab versus anti-PD-1 monotherapy was associated with a nonsignificantly lower risk of death (adjusted HR: 0.83; 95% CI: 0.54-1.28; p = 0.41), higher disease control rate (72 vs 56%; p = 0.04), and stable quality of life, but more grade 3-4 treatment-related adverse events (54 vs 26%; p < 0.0001).
Conclusion: These results support the use of immuno-oncology therapy in advanced melanoma.